glp-1 obesity drug news today september 29 2025 Lilly hikes revenue forecasts on booming sales Oral GLP-1 Pill Delivers Injection-Like

GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity

Glucagon-like peptide-1 receptor agonists, namely GLP-1 receptor agonists, are a class of drugs for the treatment of type 2 diabetes.

If you are pregnant, nursing, or taking any medications, please seek the advice of a healthcare provider prior to use

Investments are significant in the region, driving rapid product launches, clinical trials for new indications, and early adoption of innovative GLP-1 formulations, including oral and long-acting injectables

IntroductionWith the rise in glucagon-like peptide 1 receptor agonist (GLP-1RA) medication usage for Type 2 diabetes mellitus and weight loss, concerns have ...

Originally developed for diabetes management, these therapies have demonstrated significant effectiveness in weight management and are reshaping conversations around obesity treatment, chronic disease prevention, and long-term healthcare costs